中医药联合免疫检测点抑制剂治疗非小细胞肺癌临床进展及展望
Clinical Progress and Prospect of Traditional Chinese Medicine Combined with Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer
摘要: 肺癌是所有癌种中发病率及死亡率最高的，免疫检测点抑制剂作为新起的热门治疗肺癌的手段，在临床上被应用于中晚期肺癌患者，但其只能带给部分患者长期获益，而祖国医学一直在治疗肺癌方面颇有疗效，尤其是扶正治疗对于免疫有一定的调节作用，本文从免疫检测点抑制剂治疗、中医药调节免疫作用以及联合治疗方面进行简要概述。
Abstract: Lung cancer has the highest incidence and mortality among all types of cancer. Immune checkpoint inhibitors, as a newly popular means to treat lung cancer, have been clinically applied to patients with middle and advanced lung cancer. However, they can only bring long-term benefits to some patients, and the medicine of the motherland has been quite effective in the treatment of lung cancer, especially the Fuzheng treatment has a certain regulatory effect on immunity. In this paper, the treatment of immune checkpoint inhibitors, the regulation of immune function of traditional Chinese medicine and combined therapy were briefly reviewed.
文章引用：郭文韬. 中医药联合免疫检测点抑制剂治疗非小细胞肺癌临床进展及展望[J]. 临床医学进展, 2022, 12(12): 11735-11739. https://doi.org/10.12677/ACM.2022.12121690

参考文献

[1] Bray, F., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
[2] Wei, M.M. and Zhou, G.B. (2016) Long Non-Coding RNAs and Their Roles in Non-Small-Cell Lung Cancer. Genomics Proteomics & Bioinformatics, 14, 280-288. [Google Scholar] [CrossRef] [PubMed]
[3] Nicholson, A.G., Chansky, K., Crowley, J., et al. (2016) The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 11, 300-311.
[4] 尚聪聪, 张力. 非小细胞肺癌免疫治疗进展[J]. 中国肿瘤临床, 2018, 45(4): 205-208.
[5] Hazemi, A., et al. (2018) Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer. Cancer: A Journal of the American Cancer Society, 124, 248-261.
[6] Morgensztern, D. and Herbst, R. (2016) Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 22, 3713-3717. [Google Scholar] [CrossRef] 
[7] Allison, J.P. and Allison, J.P. (2015) Breakthrough of the Year 2013. Cancer Immunotherapy.
[8] Steven, A., Fisher, S.A. and Robinson, B.W. (2016) Immunotherapy for Lung Cancer. Respirology, 21, 821-833. [Google Scholar] [CrossRef] [PubMed]
[9] Langer, C.J., et al. (2016) Carboplatin and Pemetrexed with or without Pembrolizumab for Advanced, Non-Squamous Non-Small-Cell Lung Cancer: A Randomised, Phase 2 Cohort of the Open-Label KEYNOTE-021 Study. The Lancet Oncology, 17, 1497-1508. [Google Scholar] [CrossRef] 
[10] Kandalaft, L.E., Motz, G.T., Busch, J., et al. (2011) Angi-ogenesis and the Tumor Vasculature as Antitumor Immune Modulators: The Role of Vascular Endothelial Growth Factor and Endothelin. Current Topics in Microbiology and Immunology, 344, 129-148. [Google Scholar] [CrossRef] [PubMed]
[11] Socinski, M.A., Jotte, R.M., Federico, C., et al. (2018) Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. New England Journal of Medicine, 378, 2288-2301. [Google Scholar] [CrossRef] 
[12] Antonia, S.J., Villegas, A., Daniel, D., et al. (2017) Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 377, 1919-1929. [Google Scholar] [CrossRef] 
[13] Tarrio, M.L., Grabie, N., Bu, D.X., et al. (2012) PD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis. Journal of Immunology, 188, 4876-4884. [Google Scholar] [CrossRef] [PubMed]
[14] Herbst, R.S., Baas, P., Kim, D.W., et al. (2015) Pembrolizumab versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial. The Lancet, 387, 1540-1550. [Google Scholar] [CrossRef] 
[15] Postow, M.A. (2015) Managing Immune Check-point-Blocking Antibody Side Effects. American Society of Clinical Oncology Educational Book, 35, 76-83. [Google Scholar] [CrossRef] 
[16] 黄帝内经素问[M]. 周鸿飞, 范涛, 点校. 郑州: 河南科学技术出版社, 2017: 34, 164.
[17] 严用和. 重订严氏济生方[M]. 北京: 人民卫生出版社, 1980: 58.
[18] 朱克春, 肖桦, 马萍, 等. 中医药对肺癌患者免疫功能影响的研究进展[J]. 中西医结合心血管病电子杂志, 2020, 8(20): 141.
[19] 刘嘉湘. 金复康口服液治疗非小细胞肺癌的临床观察[J]. 中医杂志, 1997, 38(12): 727-729, 708.
[20] Su, X., et al. (2019) Systems Pharmacology Uncover the Mechanism of Anti-Non-Small Cell Lung Cancer for Hedyotis diffusa Willd. Biomedicine & Pharmacotherapy, 109, 969-984. [Google Scholar] [CrossRef] [PubMed]
[21] Wei, D.M., et al. (2018) Yangyin Fuzheng Decoction Enhances Anti-Tumor Efficacy of Cisplatin on Lung Cancer. Journal of Cancer, 9, 1568-1574. [Google Scholar] [CrossRef] [PubMed]
[22] 吴继, 徐振晔, 王中奇, 等. 抗瘤增效方治疗晚期非小细胞肺癌的临床研究[J]. 中国中西医结合杂志, 2010, 30(2): 137-140.
[23] 李明花, 柴水珍, 董志毅, 等. 中医药辅助PD-1单抗治疗非小细胞肺癌的临床辨析[J]. 上海中医药杂志, 2021, 55(10): 28-30, 33.
[24] 梁任隆, 赖宇, 余倩如, 等. 中医药调控肺癌肿瘤微环境研究进展[J]. 亚太传统医药, 2020, 16(2): 207-210.
[25] 谭炜焓, 金钊, 王倩, 等. PD-1/PD-L1抑制剂的中药性能探讨[J]. 新中医, 2020, 52(12): 206-208.

为你推荐